News and Trends 2 Mar 2023 Antiverse identifies therapeutic antibodies targeting GPCRs …blocking function, making them ideal starting points as therapeutic assets. The antibodies were identified using Antiverse’s proprietary computational antibody drug discovery platform, which uses machine learning to model antibody-antigen interactions… March 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2019 Janssen and Genmab Team Up Again for Another Potential Cancer Blockbuster Janssen and the Danish biotech Genmab will collaborate to develop a new antibody that could outperform their blockbuster cancer drug Darzalex in certain types of blood cancer. Genmab will develop… June 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Sep 2025 Navigating German biotech: 14 key players to know …and the space is competitive, but it’s worth keeping an eye on the Evotec spin-off. CatalYm Founded: 2016 Technology: Anti-GDF-15 monoclonal antibody Lead candidate: Visugromab CatalYm, a spin-out from Würzburg… September 23, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Belgian Antibody Proves Effective to Treat Myasthenia Gravis …Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease that… December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2025 Top biotech deals in November 2025 …of drug-Fc conjugate (DFC) therapies. Small molecules and peptides are bound to an antibody fragment to make these therapies. Merck will soon get a hold of Cidara’s lead candidate in phase 3 studies, CD388, a small molecule neuraminidase inhibitor… December 8, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates …with our colleagues at Genmab to develop new treatments for people affected by cancer.” GEN1053/BNT313 is a CD27 antibody based on the HexaBody technology, specifically engineered to form an antibody… August 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2017 Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II Prothena and Roche are advancing their Parkinson’s antibody to Phase II, triggering a new milestone payment from what is proving a lucrative deal for Prothena. Prothena, the largest biopharma in… July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 26 Jul 2024 Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies …said Ververken. The company’s approach revolves around its ConfoBodies, conformation-specific llama-derived antibody fragments (VHHs), which “promote GPCRs into functionally relevant states,” as Ververken put it. “ConfoBodies are used in our… July 26, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2023 BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets… April 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2022 Tubulis Rides Investment Wave in ADCs with €60M Series B …drug-to-antibody ratio as well as the linker chemistry of the ADC,” said Schumacher. For example, ADCs with very toxic payloads should pack fewer molecules per antibody, whereas candidates with milder… May 3, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2025 ASCO 2025: key highlights in cancer therapeutics …on immunotherapies, cell and gene therapies, and antibody-drug conjugates (ADCs) whereas about 10% of the content was focused on traditional modalities of chemotherapy, radiation, and surgery, according to Musaddiq Khan,… June 4, 2025 - 18 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2017 Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis …series of phase III trials with the antibody for psoriatic arthritis, as well as another head-to-head study with the anti-IL-17 antibody, Cosentyx. Boehringer Ingelheim and AbbVie have partnered to develop… October 17, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email